So Simple Trial Program
So Simple Trial Program
Start Confidently With TREMFYA® (guselkumab)
Enroll Patients in the SO SIMPLE TRIAL PROGRAM Today
The TREMFYA® So Simple Trial Program gives patients the opportunity to try TREMFYA® to determine if it's right for them.
1 Form – Easy enrollment process with 1 Prescription Enrollment Form (PEF) submitted to Janssen CarePath
3 Days – Shipment can be authorized within 3 BUSINESS DAYS after prescription.*
$0 Trial – First dose of TREMFYA® at no cost to patient
At the conclusion of the program, you and your patient decide if it is appropriate to continue treatment. Terms expire at the end of each calendar year and may change.
This Trial Offer is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends.
Please call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) for eligibility and program details.
*Shipment can be authorized within 3 business days of submitting a prescription pending patient program opt-in and scheduling shipment.
TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.
The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.